CPHI South East Asia 2025: Your gateway to ASEAN's expanding pharmaceutical landscape

KUALA LUMPUR, Malaysia, May 2, 2025 /PRNewswire/ -- As Southeast Asia's pharmaceutical industry rapidly evolves—driven by regulatory harmonization, innovation, and growing healthcare demand—CPHI South East Asia 2025 provides a vital platform to connect with regional stakeholders, showcase breakthroughs, and unlock business opportunities across the ASEAN region.

Taking place for the first time in Kuala Lumpur, Malaysia, from 16–18 July 2025, the event will bring together 8,000+ professionals, 400+ global exhibitors, and curated buyers from across Asia and beyond—positioning it as the region's most impactful pharma event.

Unlock Growth Across ASEAN's Pharma Markets

From Indonesia, Thailand, Vietnam, the Philippines to Malaysia, Southeast Asia is one of the world's most dynamic pharmaceutical regions. Governments are investing in local manufacturing, reforming regulatory systems, and opening doors to international partnerships.

Malaysia, as this year's host, plays a central role in this growth. ^[1]The country's pharmaceutical market is expected to rise from RM11.2 billion in 2022 to RM15.5 billion by 2027, supported by the New Industrial Master Plan (NIMP) 2030, which incentivizes the production of APIs, biologics, and vaccines.

^[2] Strategically located between Singapore and Indonesia, Malaysia offers streamlined access to regional distributors, CDMOs, and packaging partners—making Kuala Lumpur a strategic gateway to ASEAN-wide expansion.

Source: 1. MIDA, MITI Malaysia

2. ASEAN Pharmaceutical Industry Report

Source: 1. MIDA, MITI Malaysia

2. ASEAN Pharmaceutical Industry Report

At CPHI South East Asia 2025, you'll be able to:

• Access to high-growth markets across ASEAN with strong government backing for international pharma collaboration
• First-mover advantage in a fresh, opportunity-rich environment
• Direct connections with regional buyers, distributors, and contract manufacturers
• Connect through strategic matchmaking with pre-qualified buyers from across ASEAN.

Event Highlights

• Innovation Showcase
  Discover a broad spectrum of pharmaceutical innovations—from APIs, generic APIs, and excipients to biopharmaceuticals, herbal medicine, natural extracts, and finished dosage formulations. Explore the latest in custom manufacturing, drug delivery systems, pharma packaging, analytical & lab equipment, and pharmaceutical machinery & technology—all in one place.
• Conference
  Hear from regulators, manufacturers, and experts on key topics including clinical trials, regulatory harmonization, and ASEAN market access.
• Match & Meet (Business Matching Program)
  Connect through pre-arranged meetings with verified buyers actively sourcing products and partnerships.
• Special Zones & Activities
  Discover immersive experiences and dedicated features including the International Pavilions, Sustainability Square, Pharma Quest (Competition), and more—designed to foster innovation, education, and cross-border collaboration.

Venue: MITEC, Kuala Lumpur
Dates: 16–18 July 2025
Explore more at:  https://www.cphi.com/sea

Register to visit at:  https://cphisea.imasia-passport.com/

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

CPHI South East Asia 2025: Your gateway to ASEAN's expanding pharmaceutical landscape

GUANGZHOU, China, Jan. 11, 2026 /PRNewswire/ -- Recently, GAC's independently developed Quark E-Drive power domain control system has achieved the world's first dual certification for deeply integrated ASIL D functional safety and information security, accredited by DAkkS, Germany's national accreditation body. The certification was evaluated and issued by SGS-CSTC Standards Technical Services Co., Ltd. (SGS), a globally recognized certification authority.

ISO 26262 is the internationally recognized core standard for automotive functional safety. Within this framework, ASIL D represents the highest automotive safety integrity level, requiring near-zero tolerance for safety-critical failures. Achieving an ASIL D certification accredited by DAkkS signifies that the certified product meets the highest globally accepted standards for automotive safety.

The certified Quark E-Drive power domain control system has been in production use since February 2025, and is now deployed across multiple models under GAC's brands - HYPTEC and AION. As the industry's first electric drive power domain system based on deep integration using a single main control chip, the solution significantly reduces chip count, minimizes risks associated with chip-level failures, and boosts motor controller efficiency to as high as 99.9%. The certification confirms that GAC has completed the system's full product development lifecycle in strict compliance with ISO 26262:2018 functional safety and ISO/SAE 21434:2021 information security standards.

Throughout the project, GAC Technology Research Center worked closely with SGS experts, strengthening safety design across all development phases while ensuring engineering feasibility and an optimal user experience.

Zhao Hui, Vice President of SGS China, commented: "The successful certification highlights GAC's strong team and robust development systems. We are pleased to support the safety of the Quark E-Drive and look forward to closer collaboration."

This milestone represents a major breakthrough for GAC in e-drive safety and sets a new global benchmark for the intelligent electric vehicle industry.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

GAC's Quark Electric Drive Achieves the World's First DAkkS ASIL D Functional Safety and Information Security Dual Certification